0 (0%) | 04-23 17:51 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 6.1 | 1-year : | 6.99 |
Resists | First : | 5.22 | Second : | 5.98 |
Pivot price | 5.01 | |||
Supports | First : | 4 | Second : | 3.32 |
MAs | MA(5) : | 4.69 | MA(20) : | 5.08 |
MA(100) : | 4.43 | MA(250) : | 5.95 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 14 | D(3) : | 11.3 |
RSI | RSI(14): 44.5 | |||
52-week | High : | 12.68 | Low : | 1.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TSVT ] has closed above bottom band by 21.0%. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 4.87 - 4.89 | 4.89 - 4.91 |
Low: | 4.53 - 4.56 | 4.56 - 4.58 |
Close: | 4.58 - 4.62 | 4.62 - 4.67 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is based in Cambridge, Massachusetts. 2seventy bio, Inc. is a subsidiary of bluebird bio, Inc.
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 51 (M) |
Shares Float | 50 (M) |
Held by Insiders | 2.5 (%) |
Held by Institutions | 98.5 (%) |
Shares Short | 6,810 (K) |
Shares Short P.Month | 5,590 (K) |
EPS | -4.43 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 5.03 |
Profit Margin | -216.8 % |
Operating Margin | -560.5 % |
Return on Assets (ttm) | -22.2 % |
Return on Equity (ttm) | -77 % |
Qtrly Rev. Growth | -81 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 1.95 |
EBITDA (p.s.) | -4.03 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -167 (M) |
Levered Free Cash Flow | -115 (M) |
PE Ratio | -1.05 |
PEG Ratio | 0 |
Price to Book value | 0.91 |
Price to Sales | 2.36 |
Price to Cash Flow | -1.43 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |